Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Clinical Neuropharmacology|August 21, 2004
Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosetsMichael P Hill, Jonathan M Brotchie, Alan R Crossman, et al.
European Journal of Pharmacology|February 6, 2004
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaqueErwan Bezard, Michael P Hill, Alan R Crossman, et al.
Epilepsia|June 3, 2009
Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetamRafal M Kaminski, Michel Gillard, Karine Leclercq, et al.
The European Journal of Neuroscience|January 17, 2004
The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of ratsJessie Gu, Berkley A Lynch, Dina Anderson, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 9, 2004
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's diseaseMichael P Hill, Paula Ravenscroft, Erwan Bezard, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 26, 2003
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmosetMichael P Hill, Erwan Bezard, Steven G McGuire, et al.
Neurobiology of Disease|March 15, 2006
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamineWassilios Meissner, Paula Ravenscroft, René Reese, et al.
Epilepsia|June 20, 2012
Finding a better drug for epilepsy: preclinical screening strategies and experimental trial designMichele Simonato, Wolfgang Löscher, Andrew J Cole, et al.
Epilepsia|August 6, 2013
Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy developmentTerence J O'Brien, Elinor Ben-Menachem, Edward H Bertram, et al.
Epilepsia|February 28, 2016
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatmentHenrik Klitgaard, Alain Matagne, Jean-Marie Nicolas, et al.
Pageof 6